Cancer is a fighting word. But, Del Mar Pharmaceuticals, a recent addition to the roster of presenting companies at OneMedForum NY 2011, is ready for battle. The company's mission is to build shareholder value by rapidly developing and commercializing proven anti-cancer therapies in orphan indications where patients have failed modern biologic therapy. They have identified well-characterized small-molecules that have previously demonstrated clinical activity in both orphan and large-market cancer indications and are preparing to initiate human clinical trials in collaboration with leading cancer centers in North America. Since founding the company in April 2010, the team at Del Mar has accomplished the following milestones: Filed an IND with the US-FDA to begin clinical trials with the lead product; Filed four new patent applications; Closed a seed financing; Developed a novel, improved route of synthesis for the lead product; and were awarded a grant from the National Research Council of Canada. Jeffrey Bacha, B.Sc., M.B.A., President and CEO of Del Mar Pharmaceuticals is a seasoned executive leader with nearly twenty years of life sciences experience in the areas of operations, strategy and finance. His background includes successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. Mr. Bacha holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego.